Global bank says curing patients is not profitable enough, unlike treating them
Global banking giant Goldman Sachs has declared that curing patients of terminal illnesses, such as cancer, is not a “sustainable business model.”
The investment firm also urged investors to resist backing pioneering “gene therapy” treatments as cures are bad for business in the long term.
In an April 10 report entitled “The Genome Revolution,” the worlds 5th largest bank asks: “Is curing patients a sustainable business model?”
Analyst Salveen Richter wrote in the note to clients Tuesday says that long-term treatments garner far more revenue than “one-shot cures,” saying:
“The potential to deliver ‘one-shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy, and gene editing.
“However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies.